GCG and type 2 diabetes mellitus: Some GLP-1 RAs (albiglutide, efpeglenatide, dulaglutide, liraglutide, and once-weekly semaglutide) reduce the risk of major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) with established CVD or at high risk of CVD [19–23].